Anabolic Response to Mycoprotein and Micronutrient IngestonPIMPNCT04084652
Mycoprotein and Muscle Protein Synthetic Response
A study testing Mycoprotein ingestion in people with Anabolic Response to Mycoprotein and Micronutrient Ingeston, run by University of Exeter at 1 site in United Kingdom.
Trial summary
Dietary protein is vital for the preservation of health and optimal adaptation to training. However, traditional animal proteins come with a number of economic, environmental, and ethical issues. Read more about this study
- Who is it for?
- Ages 18 to 40 years, men onlyHealthy volunteers can take part
- Conditions the study is for
- Anabolic Response to Mycoprotein and Micronutrient Ingeston
- What is being tested?
- Mycoprotein ingestion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 24 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 15 Apr 2019to 11 Dec 2019
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 40 years
- Men only
- Healthy volunteers accepted
- Adult
Who may be able to join
- BMI between 18 and 30.
- Resistance trained
Who cannot join
- Any metabolic impairments.
- Cardio/pulmonary diseases.
- Chronic use of over the counter pharmaceuticals
- A personal or family history of epilepsy, seizures or schizophrenia.
- Allergic to mycoprotein/Quorn/edible fungi/environmental mould products.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Comparing the Muscle Protein Synthetic Response to Ingestion of Mycoprotein vs Protein Isolated From Mycoprotein
Dietary protein is vital for the preservation of health and optimal adaptation to training. However, traditional animal proteins come with a number of economic, environmental, and ethical issues. Accordingly, there is a need to develop an understanding of the utility of more sustainable non-animal derived dietary proteins to support our nutrition. Mycoprotein, produced by Quorn Foods™, has recently been shown to stimulate a greater anabolic response within skeletal muscle compared with milk protein, suggesting its utility within sports nutrition. However, it is unclear what accounted for the greater anabolic response of mycoprotein. One explanation could be the non-protein nutrients contained within mycoprotein (e.g. fibre, carbohydrate, fat or micronutrients).
Therefore, the present study will compare the muscle anabolic response between mycoprotein (MYC) as a whole food and the protein isolated from mycoprotein (PIM).
- Being tested
- Mycoprotein ingestion
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Mycoprotein ingestionDietary supplement
The ingestion of mycoprotein
| Study group | Role | What they receive |
|---|---|---|
| Mycoprotein | Experimental | Mycoprotein in its full food matrix Receives: Dietary Supplement: Mycoprotein ingestion |
| Protein Isolated from Mycoprotein | Experimental | Protein from mycoprotein isolated from the food matrix Receives: Dietary Supplement: Mycoprotein ingestion |
What is being measured
The primary outcome is the main question the study is designed to answer.
Muscle protein synthesis
The rate of synthesis of new muscle protein (Fractional Synthetic Rate %/h)
Measured: 7.5 hours
Secondary outcomes (3)
Plasma Amino Acid Kinetics
The rate of appearance of amino acids ingested in the drink
Measured: 7.5 hours
Blood Glucose
The levels of glucose in the blood
Measured: 7.5 hours
Serum Insulin
The levels of insulin in blood serum
Measured: 7.5 hours
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Sep 2019
- Study start15 Apr 2019
- Primary completion11 Dec 2019
- Study completion11 Dec 2019
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Anabolic Response to Mycoprotein and Micronutrient IngestonStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 24 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Exeter
- Sponsor type
- University, hospital or other
- Collaborators
- Quorn
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04084652
- Sponsor's protocol ID
- 190206/B/07UOE
- Acronym
- PIMP
- Status last verified
- May 2022
- First submitted
- 6 Sep 2019
- Last updated
- 27 May 2022
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 27 May 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comparing the Muscle Protein Synthetic Response to Ingestion of Mycoprotein vs Protein Isolated From Mycoprotein
- ClinicalTrials.gov ID
- NCT04084652
- Acronym / sponsor ID
- PIMP / 190206/B/07UOE
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 24 participants (actual)
- Lead sponsor
- University of ExeterUniversity, hospital or other
- Collaborators
- Quorn
- Study start
- 15 Apr 2019 (actual)
- Primary completion
- 11 Dec 2019 (actual)
- Study completion
- 11 Dec 2019 (actual)
- First posted
- 10 Sep 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Dietary protein is vital for the preservation of health and optimal adaptation to training. However, traditional animal proteins come with a number of economic, environmental, and ethical issues. Accordingly, there is a need to develop an understanding of the utility of more sustainable non-animal derived dietary proteins to support our nutrition. Mycoprotein, produced by Quorn Foods™, has recently been shown to stimulate a greater anabolic response within skeletal muscle compared with milk protein, suggesting its utility within sports nutrition. However, it is unclear what accounted for the greater anabolic response of mycoprotein. One explanation could be the non-protein nutrients contained within mycoprotein (e.g. fibre, carbohydrate, fat or micronutrients).
Therefore, the present study will compare the muscle anabolic response between mycoprotein (MYC) as a whole food and the protein isolated from mycoprotein (PIM).
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Mycoprotein | Experimental | Dietary Supplement: Mycoprotein ingestionMycoprotein in its full food matrix |
| Protein Isolated from Mycoprotein | Experimental | Dietary Supplement: Mycoprotein ingestionProtein from mycoprotein isolated from the food matrix |
Who may qualify
- Ages
- 18 to 40 years
- Sex
- Male only
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (2 listed)
- BMI between 18 and 30.
- Resistance trained
Key exclusion criteria (5 listed)
- Any metabolic impairments.
- Cardio/pulmonary diseases.
- Chronic use of over the counter pharmaceuticals
- A personal or family history of epilepsy, seizures or schizophrenia.
- Allergic to mycoprotein/Quorn/edible fungi/environmental mould products.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Mycoprotein ingestionThe ingestion of mycoprotein | Dietary supplement | Mycoprotein, Protein Isolated from Mycoprotein |
Primary outcome
Muscle protein synthesis
Time frame: 7.5 hours
The rate of synthesis of new muscle protein (Fractional Synthetic Rate %/h)
3 secondary outcomes
Plasma Amino Acid Kinetics
Time frame: 7.5 hours
Blood Glucose
Time frame: 7.5 hours
Serum Insulin
Time frame: 7.5 hours
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 May 2022.
- Individual participant dataSharing planned: No
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Mycoprotein ingestion in people with Anabolic Response to Mycoprotein and Micronutrient Ingeston, run by University of Exeter at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 27 May 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Muscle protein synthesis (time frame: 7.5 hours). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 May 2022.